Exelixis Inc (EXEL) Stock Price, Quote & News

Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosin...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 837 7000

Fax: 650 837 8300

Website: www.exelixis.com

Address:

1851 Harbor Bay Parkway, Alameda, United States

Jblack500 Jul. 14 at 2:25 PM

$BBIO $EXEL $GILD $SMMT "Moving on up to the east side. I finally got a piece of the pie.

0 · Reply

JarvisFlow Jul. 14 at 10:00 AM

UBS updates rating for Exelixis ( $EXEL ) to Neutral, target set at 38 → 43.

0 · Reply

Tangle22 Jul. 10 at 9:26 PM

$EXEL looks like on the way for BO but unable to predict at what value? 60 - 70 or 80?

0 · Reply

Jblack500 Jul. 10 at 6:32 PM

$EXEL $SMMT $BBIO strength

0 · Reply

Jblack500 Jul. 9 at 12:23 PM

$BBIO $EXEL $SMMT bbio..always great to see an analyst with an upgrade from equal weight to outperform...realistic price target

0 · Reply

IN0V8 Jul. 8 at 4:15 PM

$EXEL RBC cuts to sector perform from outperform RBC raises target price to $50 from $45

1 · Reply

StockHunter75 Jul. 7 at 3:08 PM

$EXEL buying some here.

1 · Reply

FionaTradesStocks Jul. 7 at 2:56 PM

$EXEL what a POS

1 · Reply

Tangle22 Jul. 7 at 2:44 PM

$EXEL @ZacksResearch is saying up but going down 5% ? Not sure why.

0 · Reply

ZacksResearch Jul. 7 at 2:38 PM

$EXEL is soaring with a 35.2% rally in 3 months — what's driving the surge? 🚀 Positive data from the STELLAR-303 study on zanzalintinib, combined with Cabometyx's strong demand, has boosted Exelixis' growth prospects. The biotech raised annual revenue guidance by $100M due to strong Cabometyx performance. Discover why EXEL is a Zacks Rank #2 (Buy) and see if it's a fit for your portfolio 👉 https://www.zacks.com/commentary/2565927/exelixis-surges-352-in-three-months-buy-or-sell-the-stock?cid=sm-stocktwits-2-2565927-body-839&ADID=SYND_STOCKTWITS_TWEET_2_2565927_BODY_839

0 · Reply

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

Jun 23, 2025, 12:58 PM EDT - 21 days ago

Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment

Jun 23, 2025, 10:37 AM EDT - 21 days ago

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

Jun 22, 2025, 5:00 PM EDT - 22 days ago

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Jun 20, 2025, 6:54 AM EDT - 24 days ago

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

May 23, 2025, 6:25 AM EDT - 7 weeks ago

Product Performance, Big Money Lift Exelixis

May 22, 2025, 5:17 PM EDT - 7 weeks ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

May 22, 2025, 4:05 PM EDT - 7 weeks ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

May 14, 2025, 2:53 PM EDT - 2 months ago

Exelixis: A Notable Quarter

May 14, 2025, 10:44 AM EDT - 2 months ago

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

May 13, 2025, 8:31 PM EDT - 2 months ago

Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript

May 13, 2025, 6:06 PM EDT - 2 months ago

Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

May 13, 2025, 4:07 PM EDT - 2 months ago

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 4:05 PM EDT - 2 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Apr 29, 2025, 4:05 PM EDT - 2 months ago

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Apr 29, 2025, 2:02 AM EDT - 2 months ago

EXEL Industries: Second quarter 2024–2025 sales down 3.8%

Mar 26, 2025, 9:15 AM EDT - 3 months ago

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Mar 25, 2025, 5:15 PM EDT - 3 months ago

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Mar 19, 2025, 7:09 AM EDT - 4 months ago

Exelixis Growth Continues with Big Money Boosts

Feb 25, 2025, 4:05 PM EST - 4 months ago

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Feb 21, 2025, 1:30 PM EST - 5 months ago

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Feb 20, 2025, 5:05 PM EST - 5 months ago

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

Feb 15, 2025, 11:10 AM EST - 5 months ago

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

Feb 13, 2025, 4:05 PM EST - 5 months ago

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

Feb 12, 2025, 9:04 AM EST - 5 months ago

Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow

Feb 11, 2025, 8:24 PM EST - 5 months ago

Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 4:05 PM EST - 5 months ago

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

Jan 28, 2025, 4:05 PM EST - 5 months ago

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Jan 25, 2025, 10:00 AM EST - 6 months ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

Jan 24, 2025, 2:30 PM EST - 6 months ago

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

Jan 22, 2025, 7:44 AM EST - 6 months ago

Revenues, Treatment Pipeline Driving Exelixis Higher

Jan 12, 2025, 4:00 PM EST - 6 months ago

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

Jan 10, 2025, 5:29 PM EST - 6 months ago

The Best Defensive Stocks To Hedge Against Market Uncertainty

EXC PM PPC RTX

Jan 9, 2025, 4:19 PM EST - 6 months ago

Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza

Jan 9, 2025, 9:00 AM EST - 6 months ago

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Jan 6, 2025, 4:05 PM EST - 6 months ago

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Nov 27, 2024, 4:05 PM EST - 8 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

Nov 26, 2024, 4:05 PM EST - 8 months ago

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Nov 7, 2024, 4:05 PM EST - 8 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Oct 31, 2024, 9:55 AM EDT - 9 months ago

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 29, 2024, 10:31 PM EDT - 9 months ago

Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 4:05 PM EDT - 9 months ago

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 21, 2024, 4:17 PM EDT - 9 months ago

3 Attractive Biotechs With Recent Positives

FOLD MRK TEVA XBI

Oct 18, 2024, 4:41 AM EDT - 9 months ago

Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials

Oct 15, 2024, 4:05 PM EDT - 9 months ago

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Oct 15, 2024, 1:57 PM EDT - 9 months ago

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

Oct 14, 2024, 8:00 AM EDT - 9 months ago

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

MRK

Sep 16, 2024, 8:45 AM EDT - 10 months ago

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Sep 15, 2024, 8:45 AM EDT - 10 months ago

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

Aug 28, 2024, 4:05 PM EDT - 11 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

Jblack500 Jul. 14 at 2:25 PM

$BBIO $EXEL $GILD $SMMT "Moving on up to the east side. I finally got a piece of the pie.

0 · Reply

JarvisFlow Jul. 14 at 10:00 AM

UBS updates rating for Exelixis ( $EXEL ) to Neutral, target set at 38 → 43.

0 · Reply

Tangle22 Jul. 10 at 9:26 PM

$EXEL looks like on the way for BO but unable to predict at what value? 60 - 70 or 80?

0 · Reply

Jblack500 Jul. 10 at 6:32 PM

$EXEL $SMMT $BBIO strength

0 · Reply

Jblack500 Jul. 9 at 12:23 PM

$BBIO $EXEL $SMMT bbio..always great to see an analyst with an upgrade from equal weight to outperform...realistic price target

0 · Reply

IN0V8 Jul. 8 at 4:15 PM

$EXEL RBC cuts to sector perform from outperform RBC raises target price to $50 from $45

1 · Reply

StockHunter75 Jul. 7 at 3:08 PM

$EXEL buying some here.

1 · Reply

FionaTradesStocks Jul. 7 at 2:56 PM

$EXEL what a POS

1 · Reply

Tangle22 Jul. 7 at 2:44 PM

$EXEL @ZacksResearch is saying up but going down 5% ? Not sure why.

0 · Reply

ZacksResearch Jul. 7 at 2:38 PM

0 · Reply

ZacksResearch Jul. 7 at 1:24 PM

$EXEL up 35.2% in 3 months — momentum play or time to lock in gains? 📈 Strong Cabometyx sales and positive zanzalintinib trial results are powering investor confidence. Find out if the rally still has legs 👉 https://www.zacks.com/stock/news/2565927/exelixis-surges-352-in-three-months-buy-or-sell-the-stock?cid=sm-stocktwits-2-2565927-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2565927_TEASER

0 · Reply

CrispDry Jul. 7 at 12:26 PM

$EXEL data today? $XBI

0 · Reply

DefenseMania Jul. 4 at 1:35 PM

$EXEL been here for a looooooong time 😀😉 Finally we’re going to see triple digits before EOY 2026

0 · Reply

CrispDry Jul. 4 at 4:29 AM

$EXEL option activity weird + double avg volume

0 · Reply

Liliy Jul. 3 at 7:32 PM

$EXEL from the Zacks report

0 · Reply

Jblack500 Jul. 3 at 4:53 PM

$BBIO $SMMT $EXEL The 3 bios outside the large caps that I've been pounding the table on all year. EXEL will be acquired if zanza trials succeed. I've owned ARRY,PCYC,CELG and these 3 were acquired. I can smell it

0 · Reply

Doozio Jul. 3 at 4:30 PM

On FRYdays the 🧠 shall $EXEL 🐒🍌🧠⏰♾️

0 · Reply

Liliy Jul. 3 at 4:26 PM

$EXEL what is happening?

3 · Reply

ivanhoff Jul. 3 at 3:23 PM

$EXEL has been volatile lately, but dips continue to get bought.

0 · Reply

Doozio Jul. 3 at 2:20 AM

Huckleberries n YUGE $$$$ patterns n da 🧠 shall $EXEL 🐒🍌🧠⏰♾️

0 · Reply

SparkyReturns Jul. 2 at 2:44 PM

$SMMT So, for an Investing idea. Anyone remember when I gave this tip about ICU a few times in the last week...? Yeah. Just getting started. $INCY $GMAB $EXEL

0 · Reply

JarvisFlow Jun. 30 at 11:30 AM

HC Wainwright & Co. has adjusted their stance on Exelixis ( $EXEL ), setting the rating to Buy with a target price of 47 → 53.

0 · Reply

Market Cap	12.23B
Revenue (ttm)	2.17B
Net Income (ttm)	521.27M
EPS (ttm)	N/A
PE Ratio	20.91
Forward PE	19.18
Profit Margin	24.04%
Debt to Equity Ratio	0.00

Volume	1,775,900
Avg Vol	3,568,338
Day's Range	N/A - N/A
Shares Out	272.71M
Stochastic %K	43%
Beta	0.28
Analysts	Strong Sell
Price Target	$45.74